A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT05816252
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital (Chongqing Cancer Hospital), Chongqing, Chongqing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University(Heyi Compus), Zhengzhou, Henan, China
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05642780
- Locations
- 🇺🇸
Community Clinical Research Center, Anderson, Indiana, United States
🇺🇸Westchester Medical Center, Hawthorne, New York, United States
🇺🇸Texas Oncology, P.A. Austin, TX, Austin, Texas, United States
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Conditions
- Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaUrothelial CarcinomaSmall-Cell Lung CancerEndometrial CarcinomaHead and Neck Squamous Cell CarcinomaBreast CancerCervical CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 1410
- Registration Number
- NCT04152499
- Locations
- 🇺🇸
Los Angeles Hematology Oncology Medical Group, Glendale, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
- Conditions
- HER-2 Gene AmplificationSalivary Gland TumorLung CancerRare DiseasesHead and Neck CancerBile Duct CancerProstate CancerRecurrent Prostate CancerRectal CancerRectal Cancer Stage III
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Klus Pharma Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03602079
- Locations
- 🇺🇸
Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸Stephenson Cancer Center, Oklahoma City, Oklahoma, United States